Processa Pharmaceuticals (NASDAQ:PCSA) reported an insider purchase by its Chief Financial Officer, Russell Skibsted, executed on April 15, 2026. According to the filing, Skibsted acquired 1,984 shares of the company’s common stock at a price of $2.97 per share, for a total cost of $5,892.
Following the transaction, Skibsted directly owns 4,308 shares of Processa Pharmaceuticals. The filing does not include additional commentary from company management or further context around the timing of the purchase.
The share change comes amid mixed recent performance for PCSA. Over the most recent week cited, the stock rose by nearly 15%. By contrast, the company’s shares remain down 58% when measured over the past six months.
Separately, analysis attributed to InvestingPro is noted alongside the transaction details. That analysis characterizes Processa Pharmaceuticals as appearing undervalued at current market levels and reports that the company holds more cash than debt on its balance sheet. The same source is referenced as offering nine additional tips aimed at investors in PCSA.
Context and limitations
The public filing documents the purchase amount, share count and resulting direct ownership figure, as well as recent price movement for PCSA. The filing does not quantify the percentage of outstanding shares represented by Skibsted’s holdings or provide guidance on future insider activity. The InvestingPro commentary is reported as a separate analytical observation; the filing itself contains only the transaction details.
This article presents the transaction and the accompanying data points without extrapolating motives or projecting future stock performance beyond the figures reported.